Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy

The sustained benefit of immunotherapy-based regimens in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) failure is debatable. Neither Checkmate-722 nor Keynote-789 reached the prespecified statistical level of clinical be...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Wu, Yan Ling, Bao-Dong Qin, Xiao-Dong Jiao, Ling-Yan Yuan, Yuan-Sheng Zang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/4/e008818.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
by: Kei Sonehara, et al.
Published: (2025-01-01)

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2024-12-01)

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
by: Ning Lou, et al.
Published: (2024-12-01)

The Effect of Fuzheng Yiai Decoction on the Transdifferentiation of Lung Adenocarcinoma in EGFR-TKI-Resistant Mice
by: Jianfeng Sun, et al.
Published: (2024-01-01)

Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer
by: Yuhong Ma, et al.
Published: (2024-12-01)

Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR‐TKI and Chemotherapy Treatments
by: Yen‐Shou Kuo, et al.
Published: (2025-09-01)

Triplet therapy overcomes 3rd-EGFR TKI-resistant EGFR-L858R/T790M/C797S in trans and in cis/L718Q mutation
by: Kaibo Ding, et al.
Published: (2025-03-01)

Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01)

Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
by: Lili Feng, et al.
Published: (2024-12-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2024-11-01)

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation
by: Chang Dong Yeo, et al.
Published: (2025-01-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Correction: EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
by: Ao Liu, et al.
Published: (2025-01-01)

Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
by: Alfredo Addeo
Published: (2022-06-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma
by: Liu J, et al.
Published: (2024-12-01)

Prognostic impact of <i>EGFR</i> and <i>KRAS</i> mutations in lung cancer survival during pre-tki era: the real scenario at a cancer public center of reference in Brazil
by: Thais Abreu Almeida, et al.
Published: (2019-01-01)

Central nervous system metastases of lung adenocarcinoma harboring EGFR-activating mutations: survival results from a multidisciplinary approach, including EGFR-TKIs
by: Guilherme Harada, et al.
Published: (2020-01-01)

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon *EGFR* Mutations
by: Christoforos Astaras, et al.
Published: (2020-03-01)

The HIF-1α/PKM2 Feedback Loop in Relation to EGFR Mutational Status in Lung Adenocarcinoma
by: Yuan Wang, et al.
Published: (2024-01-01)

Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression
by: Meiling Lan, et al.
Published: (2024-12-01)

Efficacy of osimertinib in advanced T790M-positive NSCLC after progression to prior EGFR-TKI: real world data from a Brazilian cohort
by: Luiz Henrique Araujo, et al.
Published: (2020-01-01)

ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer
by: M. A. Voronkova, et al.
Published: (2024-11-01)

Exciting progress in targeted therapy innovation for unresectable stage III EGFR‐mutated NSCLC: the phase III LAURA study
by: Ziyan Tong, et al.
Published: (2024-12-01)

A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy
by: Jue Zhang, et al.
Published: (2025-01-01)

Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability
by: Huiling Su, et al.
Published: (2025-02-01)

cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations
by: A. Peleg, et al.
Published: (2023-11-01)

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
by: Brian J. Thomas, et al.
Published: (2024-11-01)

The prevalence and clinical significance of EGFR mutations in non-small cell lung cancer patients in Egypt: a screening study
by: Asmaa A. Helal, et al.
Published: (2024-12-01)

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
by: Wentao Tian, et al.
Published: (2024-08-01)

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
by: Álvaro Taus, et al.
Published: (2012-01-01)

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma
by: Jeremy Slomka, et al.
Published: (2024-01-01)

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
by: Lin Zhu, et al.
Published: (2024-12-01)

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations
by: Abhimanyu Tushir, et al.
Published: (2025-01-01)

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
by: Yi Dong, et al.
Published: (2024-12-01)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
by: Li Liu, et al.
Published: (2020-05-01)

Bruceine H Mediates EGFR-TKI Drug Persistence in NSCLC by Notch3-Dependent β-Catenin Activating FOXO3a Signaling
by: Jiahui Wu, et al.
Published: (2022-04-01)

Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)